Detalles de la búsqueda
1.
Baseline cluster of differentiation 22 fluorescent intensity correlates with patient outcome after Inotuzumab Ozogamicin treatment.
Hematol Oncol
; 40(4): 734-742, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-35618655
2.
Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents.
Eur J Haematol
; 108(6): 449-459, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35156731
3.
Clinical Efficacy of Ponatinib in Philadelphia-Positive T-Cell Acute Lymphoblastic Leukemia with Extramedullary Involvement.
Acta Haematol
; 144(6): 688-692, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34130278
4.
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia.
Eur J Haematol
; 105(1): 47-55, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-32145118
5.
Acute Myeloid Leukemia Mutations: Therapeutic Implications.
Int J Mol Sci
; 20(11)2019 Jun 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31163594
6.
Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant.
Hematol Oncol
; 39(4): 580-583, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-33963566
7.
Ex vivo characterization of acute myeloid leukemia patients undergoing hypomethylating agents and venetoclax regimen reveals a venetoclax-specific effect on non-suppressive regulatory T cells and bona fide PD-1+TIM3+ exhausted CD8+ T cells.
Front Immunol
; 15: 1386517, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38812504
8.
Does Cytokine-Release Syndrome Induced by CAR T-Cell Treatment Have an Impact on the Pharmacokinetics of Meropenem and Piperacillin/Tazobactam in Patients with Hematological Malignancies? Findings from an Observational Case-Control Study.
Pharmaceutics
; 15(3)2023 Mar 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-36986882
9.
The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study.
Cancer Med
; 12(10): 11838-11848, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36999931
10.
An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia.
Blood Adv
; 6(1): 87-99, 2022 01 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34535017
11.
Release of IFNγ by Acute Myeloid Leukemia Cells Remodels Bone Marrow Immune Microenvironment by Inducing Regulatory T Cells.
Clin Cancer Res
; 28(14): 3141-3155, 2022 07 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35349670
12.
Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia.
Cancer Med
; 11(3): 618-629, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34970853
13.
Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia.
Front Oncol
; 11: 728613, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34660293
14.
Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients.
Leuk Res
; 101: 106497, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33385697
15.
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters.
Front Immunol
; 12: 804988, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-35173709
Resultados
1 -
15
de 15
1
Próxima >
>>